Currently, there are 52.35M common shares owned by the public and among those 48.78M shares have been available to trade.
The company’s stock has a 5-day price change of 74.76% and 39.20% over the past three months. ALIM shares are trading 28.24% year to date (YTD), with the 12-month market performance up to 97.15% higher. It has a 12-month low price of $2.60 and touched a high of $4.38 over the same period. ALIM has an average intraday trading volume of 97.25K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 80.90%, 67.63%, and 58.49% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Alimera Sciences Inc. (NASDAQ: ALIM) shares accounts for 83.47% of the company’s 52.35M shares outstanding.
It has a market capitalization of $290.24M and a beta (3y monthly) value of 1.17. The earnings-per-share (ttm) stands at -$1.57. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.91% over the week and 6.63% over the month.
Earnings per share for the fiscal year are expected to increase by 91.14%, and 371.43% over the next financial year.
Looking at the support for the ALIM, a number of firms have released research notes about the stock. Maxim Group stated their Buy rating for the stock in a research note on March 25, 2024, with the firm’s price target at $10. Alliance Global Partners coverage for the Alimera Sciences Inc. (ALIM) stock in a research note released on October 30, 2023 offered a Buy rating with a price target of $8. Craig Hallum was of a view on May 28, 2019 that the stock is Buy, while Rodman & Renshaw gave the stock Buy rating on April 27, 2017, issuing a price target of $4. Summer Street Research on their part issued Buy rating on November 17, 2014.
